DYADIC INTERNATIONAL Q2 FY26 earnings call DYAI

Dyadic is shifting from primarily developing technology platforms to building a commercially driven business. This transition involves shipping products, supporting customer evaluations, generating initial sales, and expanding distribution. A key aspect is improving manufacturing economics, as demonstrated by an 80% productivity increase in the animal-free recombinant human transferrin program, which is expected to reduce costs by 40%. This commercial activity is leveraged to create broader opportunities for partnerships and licensing.

The company's C1 and Dapibus platforms are being validated across various markets. The significant productivity improvement in transferrin not only enhances product economics but also serves as a data point to prospective partners, demonstrating the platform's ability to manufacture proteins more efficiently and economically. The Dapibus platform is highlighted for its repeatable product development and manufacturing capabilities across multiple enzyme classes and end markets, streamlining strain development, process optimization, and scale-up.

Biopharma programs are generating critical data for monoclonal antibodies (mAbs) and vaccine antigens, supported by partners like the Gates Foundation and CEPI. C1-produced antibodies have shown high productivity and functional characteristics comparable to established mammalian cell reference materials. A notable achievement is the C1 platform's ability to progress from plasmid to purified protein antigen in approximately 15 days, a capability crucial for pandemic preparedness and overall development timelines.

Dyadic employs a capital-efficient distribution strategy, combining selective direct sales with distributors and OEM partners. Relationships with IBT Bioservices, Proliant, Enzymes, Fermbox Bio, and BRIG Bio illustrate various stages of commercialization, from distribution to initial sales and partner-led commercial sales. These collaborations are designed to create multiple potential revenue streams for Dyadic, including direct sales, partner sales, milestones, royalties, development funding, and licensing.

Total revenue for the first six months of 2026 increased 52% to $2.1 million, primarily driven by grant-funded programs. However, Q2 FY26 revenue was flat year-over-year at $961,000, and the company reported a loss from operations of $2.1 million and a net loss of $2.1 million ($0.06 per share). The company ended Q2 with $4.8 million in cash and equivalents, leading to a 'going concern' disclosure due to insufficient capital for the next 12 months, despite being in compliance with all debt covenants.

To address liquidity concerns, Dyadic is actively evaluating a range of financing alternatives, including non-dilutive and strategic sources such as new licensing arrangements, upfront and milestone payments, royalties, and funded development programs. The objective is to increasingly fund product development through commercial revenues and partner-funded programs, thereby reducing reliance on dilutive capital and extending financial resources while carefully managing operating expenses and capital requirements.